BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $67.34 -0.5%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $116.6 million versus the consensus estimate of $119.24 million.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
- CoStar Group acquires Zonda for $800M, adding new home data
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
